Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs and CD83+ MSCs for Sepsis
NCT06882811Phase 1Recruiting
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CD83-positive mesenchymal stem cells and human umbilical cord mesenchymal stem cells in sepsis (3 arms). Primary endpoint: 28-day survival rate. Started May 2025; status: recruiting.
02
Drugs
CD83-positive mesenchymal stem cellshuman umbilical cord mesenchymal stem cells
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT06882811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06882811.